David Fox, PhD MAICD

Led Topelia, a clinical-stage biotechnology company focused on the development of novel therapeutic combinations targeting viral disease. • Advanced a proprietary therapeutic program from preclinical validation through to late-stage clinical readiness. • Oversaw successful Phase 1 clinical evaluation demonstrating safety and tolerability in human subjects. • Directed regulatory strategy and engagement across multiple jurisdictions. • Managed external CROs, CMC partners, and academic collaborators. • Led capital raising initiatives across institutional, sophisticated, and retail investor channels. • Structured and negotiated strategic and commercial partnerships.

Mezabiome is advancing the efficacy and efficiency of fecal microbiota transplants (FMT) through a proprietary suite of a device and complementary consumables. We employ a unique process to dissolve gastrointestinal biofilms, verify biofilm removal in real-time and deliver microbiota directly to the engraftment site once the biofilm is cleared. Our holistic approach represents a meaningful advancement in microbiome therapies, aligning treatment timing with the body’s readiness for microbiota restoration. This targeted strategy not only enhances microbiota transplantation, reduces disease recurrence, and improves patient outcomes but also benefits clinicians by streamlining the FMT process, providing precision tools for improved control, and reducing procedure time and complexity.

Helped obtain over $70 million in external funding for high potential biotech and medtech companies whilst providing guidance on how to navigate product development, regulatory regimes, clinical stage gates and financial strategies.

Instrumental in initiating, negotiating and executing a number of substantial commercial agreements.

Oversaw a team of 6 that managed more than $300 million in domestic / international equities and fixed income investments.

Exited via trade sale following substantial growth. Provided consulting and training services to a spectrum of clients ranging from SME, multinational, government and NGO.

Coverage was predominantly technology, media and telecommunications (TMT) with clients representing premier hedge, managed and superannuation funds.

Boutique advisory group focused on the biotech sector.

Engaged with the 120,000 members in over 90 countries and advocated at Federal, State and Territory government forums and advisory groups including ACCC, COSBOA, CSIRO and others.